IPA Valuation

Immunoprecise Antibodies Ltd

Add to Watchlist

Advanced Chart

0.443

+0.005(+1.140%)

Overview
Forecast
Valuation

IPA Relative Valuation

IPA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IPA is overvalued; if below, it's undervalued.

Historical Valuation

Immunoprecise Antibodies Ltd (IPA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.04 is considered Undervalued compared with the five-year average of 5.24. The fair price of Immunoprecise Antibodies Ltd (IPA) is between 0.68 to 3.02 according to relative valuation methord. Compared to the current price of 0.44 USD , Immunoprecise Antibodies Ltd is Undervalued By 34.97%.

Relative Value

Fair Zone

0.68-3.02

Current Price：0.44

34.97%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.11

P/B

Median3y

1.45

Median5y

2.94

-32.55

FCF Yield

Median3y

-20.00

Median5y

-12.90

Competitors Valuation Multiple

The average P/S ratio for IPA's competitors is 0.63, providing a benchmark for relative valuation. Immunoprecise Antibodies Ltd Corp (IPA) exhibits a P/S ratio of 1.04, which is 65.39% above the industry average. Given its robust revenue growth of -1.13%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

IPA.O

Immunoprecise Antibodies Ltd

1.04

Average P/S: 0.63

-1.13%